Bandaram Pharma Packtech has announced that its board meeting will be held on Saturday, May 30, 2026. The meeting will take place at the company's registered office in Bangalore. The primary agenda for the meeting is to consider the audited financial results for the fiscal year ending March 31, 2026.

Agenda for the Meeting

The board will deliberate on several key financial documents. The meeting is convened pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Items for Consideration

• Audited Financial Statements (Standalone and Consolidated) for the quarter and year ended 31.03.2026.
• Audit Report (Standalone and Consolidated) for the Quarter and Year ended 31.03.2026.
• Any other business with the permission of the Chair.

The company has informed BSE Limited regarding the scheduling of this meeting. The intimation was submitted on May 21, 2026. The financial results and audit reports, once approved, will provide a comprehensive view of the company's performance for the full fiscal year.

Meeting Details

Bandaram pharma packtech Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI (Depositories & Participants) Regulations, 2018. The submission, dated 11.04.2026, covers the quarter ended 31.03.2026 and demonstrates the company's adherence to dematerialisation compliance standards.

Regulatory Compliance Filing

The compliance certificate was submitted under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018. Chairman and Managing Director Deepak Bandaram signed the submission letter, which was addressed to BSE Limited at P. J. Towers, Dalal Street, Mumbai.

Certificate Confirmation by RTA

Cameo Corporate Services Limited, serving as the company's Registrar and Transfer Agent, issued the compliance certificate on 03rd April, 2026. The RTA confirmed that all securities received from depository participants for dematerialisation during Q4FY26 were properly processed and confirmed to the depositories.

Dematerialisation Process Compliance

The certificate validates several key compliance aspects of the dematerialisation process. Cameo Corporate Services confirmed that securities received during the quarter were appropriately accepted or rejected, and that these securities have been listed on stock exchanges where the company's earlier issued securities are already listed.

Process Verification Standards

The RTA confirmed that security certificates received for dematerialisation were mutilated and cancelled after due verification by the depository participant. Additionally, the names of the depositories have been substituted in the register of members as registered owners within the stipulated time limits under the captioned regulations.

This quarterly compliance filing demonstrates Bandaram Pharma Packtech Limited's commitment to maintaining proper regulatory standards and ensuring transparent dematerialisation processes for its shareholders.